Aaron Perlmutter, MD
Infectious Disease · Beverly Hills, CANPI 1114952496
Payments from drug & device makers
Across 447 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$3K
- EMD Serono, Inc.$603
- Johnson & Johnson$558
- Napo Pharmaceuticals Inc$402
- Merck$375
- plus $2K from 30 others
What the payments were for
- Consulting fees$2,14018%
- Speaking & faculty fees$1992%
- Food & beverage$9,49180%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 181 | $4,180 |
| Gilead | 53 | $3,227 |
| EMD Serono, Inc. | 28 | $603 |
| Johnson & Johnson(2 entities) | 30 | $558 |
| Napo Pharmaceuticals Inc | 26 | $402 |
| Merck | 21 | $375 |
| Novo Nordisk | 17 | $313 |
| AbbVie | 14 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $262 |
| Amgen | 11 | $256 |
| Antares Pharma, Inc. | 6 | $175 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $168 |
| Lilly USA, LLC | 6 | $123 |
| Theratechnologies Inc. | 5 | $105 |
| Alnylam Pharmaceuticals Inc. | 3 | $84 |
| Janssen Products, LP | 1 | $75 |
| Melinta Therapeutics, LLC | 3 | $71 |
| Kestra Medical Technology Services, Inc. | 3 | $68 |
| Verity Pharmaceuticals Inc. | 2 | $65 |
| Bayer | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Boehringer Ingelheim | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Heartflow, Inc. | 1 | $24 |
| Tris Pharma Inc | 1 | $24 |
| Concordia Pharmaceuticals Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $23 |
| Pfizer | 1 | $22 |
| Novartis | 1 | $21 |
| QOL Medical, LLC | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Itamar Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,842 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 58 | $1,106,937 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 143 | $603,809 |
| JulucaDolutegravir/Rilpivirine | 73 | $246,667 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 36 | $186,708 |
| CabenuvaCabotegravir/Rilpivirine | 23 | $163,857 |
| RukobiaFostemsavir Tromethamine | 19 | $160,832 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 31 | $121,034 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $78,855 |
| DescovyEmtricitabine/Tenofov Alafenam | 24 | $68,273 |
| OzempicSemaglutide | 60 | $65,258 |
| Darunavir | 43 | $57,745 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 15 | $52,600 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $36,374 |
| IsentressRaltegravir Potassium | 18 | $32,592 |
| TivicayDolutegravir Sodium | 12 | $26,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Serostim | $603 | $1,106,93758 claims |
| GileadBiktarvy, Genvoya, Descovy | $3,227 | $793,115198 claims |
| Viiv Healthcare CompanyJuluca, Cabenuva, Rukobia, Triumeq, Dovato | $4,180 | $713,081154 claims |
| Janssen Products, LPSymtuza | $75 | $186,70836 claims |
| Novo NordiskOzempic | $313 | $65,25860 claims |
| MerckIsentress, Januvia | $375 | $45,14842 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $29 | $30,73654 claims |
| Johnson & JohnsonPrezcobix | $558 | $25,63511 claims |
| Lilly USA, LLCMounjaro | $123 | $15,28615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $262 | $10,10921 claims |
| PfizerEliquis | $22 | $6,17813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.
Other infectious disease in Beverly Hills
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
- James McKinnellTorrance$4.3M
- Loren MillerTorrance$4.1M
- Jay GladsteinLos Angeles$4M
- Claire PomeroySacramento$3.8M
- Franco FelizartaBakersfield$3.5M
- Abhijit LimayeSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.